1 January 2009 in Thyroid Research
Human endocrine tumors often express the somatostatin receptors SSTR 1–5 with different intensity. It has been widely investigated their distribution in pituitary adenomas, brain tumors, adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET). Some of studies also concern the expression of SSTRs in thyroid tumors but they are mainly limited to parafollicular C cells – derived medullary thyroid carcinomas (MTC). Results of SSTR 1–5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used. The aim of this study was to report the presence of all the 5 subtypes of SSTR (including 2A and 2B SSTR isoforms) in some surgically treated human thyroid tumors by means of immunohistochemistry and real-time PCR method and to correlate the results obtained with both techniques. SSTR 1 protein was expressed in 88.8% of investigated cases, SSTR 2A and 2B both in 44.4%, SSTR 3 in 55.5%, SSTR 4 in 11.2% and SSTR 5 in 33.3%. SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. We found positive confirmation of both methods in 88.8% for SSTR 1, 2A, 3 subtypes, in 22.2% for SSTR 4 and in 100% for SSTR 5. It suggests that somatostatin multiligand analogs or selective SSTR 1 agonists may be used in thyroid tumors treatment.
1 April 2003 in Life Sciences
1 September 2025 in Polish Journal of Surgery
Introduction: The analysis of exercise tolerance and physical capacity plays a crucial role in the assessment of recovery and rehabilitation after surgery.Aim: The aim of the study was to assess physical capacity, exercise tolerance prior to and on day 2 after adrenalectomy on the basis of the six-minute walk test (6MWT) and Borg scale.Material and methods: The cohort study included 100 patients with adrenal tumors divided into the study group (SG,n = 50) and control group (CG, n = 50) who underwent adrenalectomy. SG patients met the criterion of inclusion: coexistingcardiovascular, respiratory, or other chronic diseases. The inclusion criteria for CG were the absence of other chronic systemiccomorbidities, age < 65 years. The 6MWT distance and Borg scale ratings (performed the day prior to and on the secondday after surgery) were analyzed according to the age, sex, comorbidities, adrenal and tumor size, hormonal type of adrenaldisease, type of surgery, and occurrence of postoperative complications.Results: Patients from SG covered significantly shorter distances (487.76 46.72 m in SG and 539.82 17.59 m in CG; p<0.001) anddemonstrated a higher level of exertion (p<0.001) before adrenalectomy and more often discontinued 6MWT after surgeries(p = 0.001) compared to CG. The authors confirmed a significant negative correlation between the age of the patients and sixminute walk distance (6MWD) before the operation in the study (rs = –0.40, p = 0.004) and control (rs = –0.74, p<0.001) groups.A significant decrease in the postoperative 6MWT distance (SG: to 231.35 4192 m, CG: to 236.82 54.10 m) and increasedintensity of dyspnea and fatigue according to the Borg scale were confirmed. SG patients were significantly more likely todevelop postoperative complications (p = 0.002).Conclusions: 6MWT is a useful tool to demonstrate physical capacity in patients before and after adrenalectomy. Patients with comorbidities more frequently discontinued 6MWT after surgery and had lower tolerance of physical effort compared to CG patients before and after surgery.